AbCellera Biologics Inc. (ABCL) Institutional Ownership

Ownership Summary

AbCellera Biologics Inc. (NASDAQ:ABCL) has 144 institutional investors with active 13F positions as of December 2025.

• These investors collectively held 36.3% of AbCellera Biologics's outstanding shares in December 2025, up from 35.9% in September 2025.
• Their total shares held in ABCL increased 17.72% from the prior quarter, while the number of investors in AbCellera Biologics increased 1.41% year over year.
• Among the 144 funds, 80 bought more AbCellera Biologics shares, 38 sold down, and 26 held their ground.
• Combined, these investors held 108.59Mn shares in ABCL for December 2025, up by 16.35Mn shares quarter on quarter, and down 17.01Mn shares year over year.
• As of December 31, 2025, BAKER BROS. ADVISORS LP held the largest stake in AbCellera Biologics with 30.28Mn shares, accounting for 10.13% of total shares outstanding.
• Top purchasers of ABCL stock for the quarter ending December 2025 included TD Waterhouse Canada Inc. (9.54Mn), TWO SIGMA INVESTMENTS, LP (4.75Mn), BAKER BROS. ADVISORS LP (2.75Mn), Jefferies Financial Group Inc. (2.75Mn), Alyeska Investment Group, L.P. (2.59Mn).
• The largest sellers of AbCellera Biologics for the quarter ending December 2025 were Goldman Sachs Group Inc (4.94Mn), RENAISSANCE TECHNOLOGIES LLC (878.6K), Morgan Stanley (777.02K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (774.17K), JANE STREET GROUP, LLC (549.21K).
• According to Business Quant data, leading holders of ABCL for December 2025 are BAKER BROS. ADVISORS LP (30.28Mn), Capital World Investors (13.36Mn), TWO SIGMA INVESTMENTS, LP (10.56Mn), TD Waterhouse Canada Inc. (9.56Mn), UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (7.58Mn), UBS Group AG (4.21Mn), ArrowMark Colorado Holdings LLC (4.11Mn), BlackRock, Inc. (4.04Mn), DRIEHAUS CAPITAL MANAGEMENT LLC (4.02Mn), Goldman Sachs Group Inc (3.75Mn).